A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The researchers then investigated how the metabolisms of treated mice changed. They found that the effect was caused by ...

研究人员选择研究Semaglutide作为潜在治疗方法，因为这一类药物有助于减少MASH患者的脂肪和肝脏疤痕。Newsome教授此前在《柳叶刀》和《新英格兰医学杂志》上发表的小规模积极研究表明，使用Semaglutide治疗MASH对患者有益。

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.